Trial Profile
An open-label randomised trial to investigate cetuximab monotherapy and the combination of cetuximab and irinotecan in patients with irinotecan-refractory, EGFR-expressing colorectal cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2010
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms BOND
- Sponsors Merck KGaA
- 05 Nov 2010 New trial record.